Epidemiological study on gene mutations and prognosis of solid tumors using C-CAT data

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031240203

Enrollment

50000

Registered

2024-07-03

Start date

2024-07-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects with solid tumors must meet the following criteria:. 1) Have undergone FoundationOne CDx gene panel testing between June 1, 2019 and April 30, 2024. 2) Have a histological diagnosis consistent with the recorded cancer type.

Exclusion criteria

Exclusion criteria: Patients aged < 18 years at the time of enrollment in C-CAT

Design outcomes

Primary

Measure	Time frame
To estimate the prevalence of mutations in genes that could be new therapeutic targets across cancer types in the C-CAT database.	—

Secondary

Measure	Time frame
The frequency of co-mutations by cancer type in the C-CAT database will be described. Survival will be described by genetic mutation by cancer type in the C-CAT database.	—

Contacts

Public ContactContact Local

Amgen K.K.

clinicaltrials_japan@amgen.com+81-80-7217-8592

Outcome results